Humacyte, Inc. (HUMA) SEC Filings & Earnings Calls

Strategic partner exit risk

“The reporting persons ceased to beneficially own more than five percent of the Issuer's Common Stock on August 17, 2026.” · word for word

Strategic partner exit risk

“The reporting persons ceased to beneficially own more than five percent of the Issuer's Common Stock on August 17, 2026.” · word for word

Going concern uncertainty

“We will not have sufficient liquidity to fund our operations beyond one year from the issuance of these interim financial statements if we are unable to generate sufficient cash flows from commercial sales on a timely basis and/or obtain additional capital. These factors raise substantial doubt about our ability to continue as a going concern.” · word for word

Commercial adoption risk

“Our ability to generate sufficient product revenue to finance our operations will depend on the successful commercialization of Symvess” · word for word

Dilution risk

“Our net proceeds from the 2026 Public Offering, including the sale of the 2026 Option Shares, were approximately $53.8 million after deducting underwriting discounts and commissions and offering expenses.” · word for word

Regulatory approval risk for sBLA filing; commercial adoption still early.

“sBLA to be filed in H2 2026; approval not guaranteed.”

Potential delisting from Nasdaq if bid price does not recover within 180 days.

“There can be no assurance that the Company will regain compliance during this period.” · word for word

Major shareholder exit risk

“FMCH established a trading plan ... to sell 5,000,000 shares of the Issuer's Common Stock ... The sale of all shares ... will reduce FMCH's and FME AG's beneficial ownership below 5%”

Major shareholder exit risk

“FMCH established a trading plan ... to sell 5,000,000 shares of the Issuer's Common Stock ... The sale of all shares ... will reduce FMCH's and FME AG's beneficial ownership below 5%”

Significant dilution from equity offering; biotech cash burn risk.

“Item 1.01: 47.6M shares, ~$46.8M proceeds.”

Going concern / liquidity risk

“We will not have sufficient liquidity to fund our operations beyond one year from the issuance of these condensed consolidated financial statements if we are unable to generate sufficient cash flows from commercial sales on a timely basis and/or obtain additional capital.” · word for word

Nasdaq delisting risk

“On May 4, 2026, we received a letter from the staff of The Nasdaq Stock Market LLC providing notification that, for the 30 consecutive business days ended May 1, 2026, the bid price for the Company’s Common Stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)” · word for word

Securities class action litigation

“On November 18, 2024, James A. Cutshall filed a putative class action lawsuit, captioned Cutshall v. Humacyte, Inc., et al., No. 1:24-cv-00954 (the 'Securities Litigation'), against the Company and certain of the Company’s officers in the United States District Court for the Middle District of North Carolina.” · word for word

Equity dilution risk

“On March 19, 2026, the Company entered into certain securities purchase agreements, pursuant to which the Company agreed to issue and sell to certain investors in a registered direct offering 25,000,000 shares of Common Stock at a price of $0.80 per share.” · word for word

Risk of delisting if bid price not regained within 180 days.

“the Company has been provided an initial period of 180 calendar days, or until November 2, 2026, to regain compliance.”

Share Dilution Risk

“Proposal 5: Approval of an amendment to the Certificate of Incorporation to increase the total number of authorized shares of common stock from 350,000,000 to 550,000,000 shares.” · word for word

Insider Ownership Concentration

“All Directors and Executive Officers of Humacyte as a Group (14 Individuals) 6,898,604 3.1%” · word for word

Clinical trial failure risk

“The V006 study did not meet its primary efficacy endpoint regarding secondary patency at 24 months.”

Market size estimation risk

“The sizes of the market opportunities for our product candidates have not been established with precision and are estimates that management believes to be reasonable.” · word for word

Regulatory approval risk for AV access

“Subject to the outcome of the interim data analysis of the V012 clinical trial, we expect to file a BLA with the FDA in the second half of 2026 seeking approval for the use of ATEV in AV access for hemodialysis.” · word for word

No specific risks identified in excerpt; standard forward-looking statements.

“Risk Factor Updates, dated March 19, 2026.” · word for word

Commercial adoption still early; only 16 hospitals have ordered despite 92 eligible.

“16 hospitals ordered vs 92 eligible; 45 VAC committees still reviewing.”

Operating losses continue as company invests in commercial and R&D.

“No profitability disclosed; net loss implied from context.”

Cash runway risk

“As of September 30, 2025, we had cash and cash equivalents of $19.5 million and restricted cash of $0.4 million. We believe our cash and cash equivalents on hand and existing capacity under our Common Stock Purchase Agreement will be sufficient to fund operations for at least 12 months from the date of this Quarterly Report.” · word for word

Commercialization risk

“We have only recently generated revenue from the sale of commercialized products. Our ability to generate product revenue will depend on the successful development and commercialization of Symvess and our product candidates.”

Inventory obsolescence risk

“If market acceptance of Symvess does not occur at all or on a timely basis prior to the inventory shelf-life expiration, we may be required to write-off some or all inventory.” · word for word

Regulatory risk (NTAP denial)

“In July 2025, CMS declined to approve our NTAP application. We believe that the potential impact of the NTAP on commercial success is limited as only approximately 4.3% of vascular trauma patients are covered under Medicare reimbursement.” · word for word